The role of androgens on cognitive function and mood is not well documented yet. We therefore evaluated all male participants (n ¼ 247, mean age 75.7 years) of a population-based study regarding testosterone, dehydroepiandrosterone sulfate (DHEAS), depression and Alzheimer Dementia (AD) for 5 years using the DSM-IV and NINCDS-ADRDA criteria. At study entry, low serum testosterone levels (o350 ng per 100 ml) were present in 45 (30.8%), low DHEAS (o50 lg per 100 ml) in 44 (30.1%), depression in 11 (7.5%) and AD in 7 (4.7%) men. After 5 years, the number of men with low testosterone levels increased to 52 ( þ 15.5%), for low DHEAS to 57 ( þ 29.5%) for depression to 34 ( þ 219%) and for AD to 43 ( þ 515%). Testosterone levels were not associated to prevalence or incidence of depression or dementia. Mean testosterone was 398.1 ng per 100 ml in depressive men and 431.7 ng per 100 ml in those without depression (P ¼ 0.57) and 406.3 ng per 100 ml in those with AD versus 429.5 ng per 100 ml without AD (P ¼ 0.66).
Introduction
The continuous decline of testosterone and DHEAS serum levels in the male aging process is well documented, and low androgen levels have therefore become an area of clinical interest. [1] [2] [3] Low testosterone levels have been linked to a variety of symptoms such as reduced muscle mass, low bone mineral density, impairment of libido, sexual performance, well-being and cognitive function and an increase of mood disorders. [4] [5] [6] Although data regarding the effect of androgens on somatic parameters, such as bone mineral density or lean body mass, are quite robust, the effect of late-onset hypogonadism for the genesis of reduced 'cognitive function' or 'mood disorders' is poorly understood. The potential association is of considerable interest as depression and Alzheimer dementia (AD) belong to the most prevalent diseases in aging western populations. [7] [8] [9] [10] [11] The available literature mainly consists of small, short-term studies and animal data. A consistent relationship between testosterone and dehydroepiandrosterone sulfate (DHEAS) levels on the one hand and depression and AD on the other has not been sufficiently supported. 5 We therefore analyzed the association between depression and AD to total testosterone and DHEAS serum levels in aging men. All men were participants of the Vienna Transdanube Aging (VITA) study, which is a longitudinal, population-based study of men all aged 75 years of age at baseline living in two districts in Vienna. The VITA study was primarily designed to identify risk factors and predictors for AD. 12 
Materials and methods
The VITA study The VITA study is a prospective, population-based, cohort study of all 75-year-old inhabitants of the 21st and 22nd district of Vienna located east of the river Danube. All men and women, who were at the beginning of the study 75 years of age, were invited to participate (n ¼ 1.920). Of those, a total of 1505 could be contacted and 606 subjects (247 men) agreed to participate and underwent the baseline investigation. The VITA study was initiated in 2000 with the main scientific question to identify predictors for AD in the elderly. The study was initiated and is conducted by the Ludwig Boltzmann Institute of Aging Research in close cooperation with the Danube Hospital, a large community hospital in this area.
The study was approved by the Viennese medical ethic committee and written informed consent was obtained from all participants. Study design, recruitment and clinical investigations were published in detail in 2007. 12 Men with any form of cancer (including prostate or testicular cancer) were excluded from the final analysis. None of the participants got any hormonal treatment.
Androgen levels
According to recent guidelines, low serum testosterone level was defined as o350 ng per 100 ml. 5 As the VITA study was not primarily designed for lateonset hypogonadism analysis, free testosterone and sexual hormone binding protein (SHBG) were not measured.
As a specific definition of low DHEAS does not exist, a cutoff of 50 mg per 100 ml was chosen. This cutoff provides a comparable proportion of affected men compared with the cutoff for total testosterone (about 30%).
All hormones were collected between 08:00 and 10:00 hours in the morning.
Endocrine study
The following endocrine parameters were determined.
Testosterone: Radioimmuno assay (Coat-A-Count Total Testosterone, DPC-Bü hlmann GmbH, Salzburg, Austria); limit of detection: 4 ng per 100 ml.
DHEAS: Radioimmuno assay (Immunotech, Marseille, France); limit of detection: 6 mg per 100 ml.
Luteinizing hormone: Immunoradiometric assay (RIA-gnost hLH CIS bio international, Gif-SurYvette, France); limit of detection: 0.02 mg per 100 ml.
Follicle-stimulating hormone:
Immunoradiometric assay (RIA-gnost hFSH, CIS bio international, Gif-Sur-Yvette, France); limit of detection: 0.2 IU l -1 .
Depression
Depression was assessed according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorder criteria). 13 According to a semi-structured interview, provided by a professional psychologist (S.J.), 9 different symptoms of depression are judged (A1 depressed mood, A2 diminished interest, A3 weight loss or gain, A4 insomnia, hypersomnia, A5 psychomotor agitation or retardation, A6 loss of energy, A7 feelings of worthlessness, A8 thinking concentration and A9 suicidality) and classified to:
No depression: no or just a single symptom Subsyndromale depression: 2-7 symptoms but not A1 or A2 Minor depression: 2-4 symptoms; symptom A1 or A2 fulfilled Major depression: 5-9 symptoms; symptom A1 or A2 fulfilled For this analysis we summarized minor and major depression as depression.
Alzheimer dementia
Alzheimer Dementia (AD) was evaluated and classified according to NINCDS-ADRDA Alzheimer's Criteria (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association).
14 Possible and probable AD were summarized as AD.
Statistical analysis
All statistical analyses were conducted using the Statistical Package for Social Sciences, version 10.0.7 (SPSS Inc., Chicago, IL, USA). For the development of testosterone and DHEAS over time analysis of variance and Pearson's chi-quadrate-test were performed. Relevance of baseline testosterone and DHEAS versus prevalence (baseline) and incidence (after 5 years) of depression and AD was analyzed using Pearson's chi-quadrate-test. A two-sided P-value o0.05 was considered to be significant.
Results
Characteristics of the study population at baseline A total of 247 men with a mean age of 75.8 years (range: 74.9-77.6 years) entered the analysis at baseline. Mean total testosterone was 424 ng per 100 ml (range: 6-1327 ng per 100 ml) and mean DHEAS 83 mg per 100 ml (range: 1-366 mg per 100 ml).
At study entry, 30.3% (n ¼ 75) had low testosterone and 30.1% (n ¼ 74) men had low DHEAS. Depression was present in 18 (7.2%) and AD in 12 (4.8%) men (data not shown).
Baseline population (n ¼ 247) was almost identical to the cohort of men with complete 5-years follow-up (n ¼ 146) (see Table 1 ).
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Androgens and prevalence of depression and AD at baseline At baseline, prevalence of depression and AD was comparable when stratified to testosterone o/X350 ng per 100 ml and DHEAS o/X50 mg per 100 ml (Table 2) . Mean testosterone was 398.1 ng per 100 ml in depressive men and 431.7 ng per 100 ml in those participants without minor/major depression (P ¼ 0.57); the corresponding figures for DHEAS were 78.0 versus 83.3 mg per 100 ml (P ¼ 0.89).
Regarding AD, mean testosterone was 406.3 ng per 100 ml in affected men versus 429.5 ng per 100 ml in those without AD (P ¼ 0.66); corresponding results for DHEAS were 81.5 and 82.6 mg per 100 ml (P ¼ 0.93).
Longitudinal data
Out of this baseline population, after 60 month of follow-up 51 died, 32 were lost to follow-up and 18 were excluded because of incomplete androgen status.
Total serum testosterone levels remained stable; mean values were 429.2 ng per 100 ml at baseline, 438.2 ng per 100 ml after 30 months and 415.5 ng per 100 ml after 60 months. The corresponding figures for DHEAS serum levels were 82.9, 78.8 and 80.4 mg per 100 ml (see also Figure 1 ).
Both depression and AD increased significantly over time from 7.5% (n ¼ 11) to 23.3 (n ¼ 34) after 30 and 60 months regarding depression and from 4.7 (n ¼ 7) to 15.7% (n ¼ 23) and 29.5% (n ¼ 43) regarding AD (both: Po0.05) ( Table 3) .
Androgens and incidence of depression and AD over 5 years As listed in Table 4 , new incidence of depression and AD did not differ between low testosterone/ DHEAS versus normal androgen levels. A trend was just seen for incidence over 5 years regarding AD. New incidence of AD was higher (but not Serum androgen levels and their association to depression and AD A Ponholzer et al significantly) in participants with low DHEAS (31.8%) compared with men with normal DHEAS (21.8%). After 5 years, men with depression had a mean testosterone level of 387.3 ng per 100 ml compared with 424.1 ng per 100 ml in those who are not suffering from depression, and DHEAS levels of 70.1 mg per 100 ml (minor/major depression) versus 83.3 mg per 100 ml (no depression) (both not significant).
The corresponding figures after the 5-year study period for AD were 417.8 ng per 100 ml (AD) versus 414.6 ng per 100 ml (no AD) for total testosterone, and 76.2 versus 82 mg per 100 ml for DHEAS (both not significant).
Discussion
What we found in our population-based cohort comprising of 247 men at the age of 75 at study entry and 146 completing the whole studyperiod over 5 years can be summarized in mainly four points:
Testosterone and DHEAS remained relatively constant during the 5-year observation period. Depression and AD increased significantly from 7.5 and 4.7% at baseline to 23.3 and even 29.5% after 5 years. Regarding AD in particular, the 6-fold increase in 5 years underlines the importance of a more detailed picture regarding risk factors for this 'epidemia' of old ages. Androgens are not associated to baseline prevalence or the new incidence of minor/major depression or AD. Mean testosterone in the baseline population was 398.1 ng per 100 ml in depressive men and 431.7 ng per 100 ml in those participants without depression (P ¼ 0.57); mean testosterone was 406.3 ng per 100 ml in affected men versus 429.5 ng per 100 ml in those without AD (P ¼ 0.66). This difference may be false negative (lack of significance) because of the small sample size.
According to the ongoing discussion on the clinical relevance of decreasing androgen levels during the male aging process, testosterone and DHEAS may have an effect on the genesis of mood disorders and impaired cognitive performance.
The high prevalence of both disorders in more advanced age-groups and their substantial socioeconomic effect were the scientific basis for this study, that is, to evaluate the association and correlation between serum androgen levels and AD and depression. In doing so we studied a population-based cohort with a very narrow age range. Our data are therefore not biased by the confounder 'age'. Further strengths of our study are its longitudinal design and the use of validated instruments to assess AD and depression. Limitations are the sample size (in particular of those who completed the 5 year-study period) and the fact that free testosterone and SHBG were not quantified.
Amiaz and Seidman 7 recently reviewed the role of testosterone in the genesis of depression in men reporting four epidemiological studies, which showed contradictive results and mixed effects. [15] [16] [17] Only in one out of these men, the Rancho Bernardo Study described a significant inverse correlation between Beck Depression Inventory and bioavailable, but not total testosterone. 16 For example, Kratzik et al. found out in their Androx study that the risk for depression was increased for hypogonadal and hypergonadal men with an U-shaped effect in underweight and obese men, a phenomenon which was rather similarly described by Booth et al. in their Veterans Experience study. 17, 18 Another interesting recent study investigating 157 men referring to an ED clinic showed a relative risk 
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A timely overview over the role of androgens in the genesis of AD was provided by Fuller et al. 8 According to their comprehensive work, and mainly according to animal and cell biology studies, androgens may play a protective role. Also in epidemiological studies, low testosterone levels have already been associated with an increased risk of (mainly vascular) dementia and some preliminary reports, even suggest that androgen replacement therapy may improve cognition in vascular dementia patients. 20, 21 However, a recent study contradicts these findings, as endogenous testosterone levels were not found to be associated with risk for cognitive decline in a group of men aged 71-93 years over a period of 6 years, showing, once again, the controversies in this field. 22 Having the large body of heterogeneous studies investigating this topic in mind, it seems quite difficult to compare our data with earlier published work, mainly because of the different definition of depression or AD and different population age.
In fact, we consider our results as highly representative and robust as the work up and definition of depression and AD were carried out according to a standardized and validated protocol. The only drawbacks of our setting may be the lack of free testosterone or bioavailable testosterone measurements and the possibly false negative error because of the lack of statistical power in our sample size.
In conclusion, over a period of 5 years, in this population-based cohort of men aged 75 years at study entry, low testosterone or DHEAS levels remained relatively stable, and were not associated to prevalence and new onset of depression or AD.
